These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 10823952)

  • 1. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates.
    Habib KE; Weld KP; Rice KC; Pushkas J; Champoux M; Listwak S; Webster EL; Atkinson AJ; Schulkin J; Contoreggi C; Chrousos GP; McCann SM; Suomi SJ; Higley JD; Gold PW
    Proc Natl Acad Sci U S A; 2000 May; 97(11):6079-84. PubMed ID: 10823952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Behavioral, adrenal, and sympathetic responses to long-term administration of an oral corticotropin-releasing hormone receptor antagonist in a primate stress paradigm.
    Ayala AR; Pushkas J; Higley JD; Ronsaville D; Gold PW; Chrousos GP; Pacak K; Calis KA; Gerald M; Lindell S; Rice KC; Cizza G
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5729-37. PubMed ID: 15531536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corticotropin-releasing hormone antagonists, astressin B and antalarmin: differing profiles of activity in rhesus monkeys.
    Broadbear JH; Winger G; Rivier JE; Rice KC; Woods JH
    Neuropsychopharmacology; 2004 Jun; 29(6):1112-21. PubMed ID: 14997174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress.
    Deak T; Nguyen KT; Ehrlich AL; Watkins LR; Spencer RL; Maier SF; Licinio J; Wong ML; Chrousos GP; Webster E; Gold PW
    Endocrinology; 1999 Jan; 140(1):79-86. PubMed ID: 9886810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coping with chronic social stress in mice: hypothalamic-pituitary-adrenal/ sympathetic-adrenal-medullary axis activity, behavioral changes and effects of antalarmin treatment: implications for the study of stress-related psychopathologies.
    Pérez-Tejada J; Arregi A; Gómez-Lázaro E; Vegas O; Azpiroz A; Garmendia L
    Neuroendocrinology; 2013; 98(1):73-88. PubMed ID: 23796983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antalarmin, a putative CRH-RI antagonist, has transient reinforcing effects in rhesus monkeys.
    Broadbear JH; Winger G; Rice KC; Woods JH
    Psychopharmacology (Berl); 2002 Nov; 164(3):268-76. PubMed ID: 12424550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence of lasting dysregulation of neuroendocrine and HPA axis function following global cerebral ischemia in male rats and the effect of Antalarmin on plasma corticosterone level.
    de la Tremblaye PB; Raymond J; Milot MR; Merali Z; Plamondon H
    Horm Behav; 2014 Mar; 65(3):273-84. PubMed ID: 24444675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated.
    Zobel AW; Nickel T; Künzel HE; Ackl N; Sonntag A; Ising M; Holsboer F
    J Psychiatr Res; 2000; 34(3):171-81. PubMed ID: 10867111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with CRH-1 antagonist antalarmin reduces behavioral and endocrine responses to social stressors in marmosets (Callithrix kuhlii).
    French JA; Fite JE; Jensen H; Oparowski K; Rukstalis MR; Fix H; Jones B; Maxwell H; Pacer M; Power ML; Schulkin J
    Am J Primatol; 2007 Aug; 69(8):877-89. PubMed ID: 17397037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic administration of the non-peptide CRH type 1 receptor antagonist antalarmin does not blunt hypothalamic-pituitary-adrenal axis responses to acute immobilization stress.
    Wong ML; Webster EL; Spokes H; Phu P; Ehrhart-Bornstein M; Bornstein S; Park CS; Rice KC; Chrousos GP; Licinio J; Gold PW
    Life Sci; 1999; 65(4):PL53-8. PubMed ID: 10421433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a novel corticotropin-releasing-hormone receptor type I antagonist on human adrenal function.
    Willenberg HS; Bornstein SR; Hiroi N; Päth G; Goretzki PE; Scherbaum WA; Chrousos GP
    Mol Psychiatry; 2000 Mar; 5(2):137-41. PubMed ID: 10822340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine, behavioral and autonomic effects of neuropeptide AF.
    Jászberényi M; Bagosi Z; Thurzó B; Földesi I; Szabó G; Telegdy G
    Horm Behav; 2009 Jun; 56(1):24-34. PubMed ID: 19269292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of a corticotropin-releasing factor receptor 1 antagonist on the fear conditioning response in low- and high-anxiety rats after chronic corticosterone administration.
    Skórzewska A; Wisłowska-Stanek A; Lehner M; Turzyńska D; Sobolewska A; Krząścik P; Szyndler J; Maciejak P; Płaźnik A
    Stress; 2019 Jan; 22(1):113-122. PubMed ID: 30345859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic effects of a nonpeptide corticotropin-releasing hormone type I receptor antagonist on pituitary-adrenal function, body weight, and metabolic regulation.
    Bornstein SR; Webster EL; Torpy DJ; Richman SJ; Mitsiades N; Igel M; Lewis DB; Rice KC; Joost HG; Tsokos M; Chrousos GP
    Endocrinology; 1998 Apr; 139(4):1546-55. PubMed ID: 9528933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with a CRH-R1 antagonist prevents stress-induced suppression of the central neural drive to the reproductive axis in female macaques.
    Herod SM; Pohl CR; Cameron JL
    Am J Physiol Endocrinol Metab; 2011 Jan; 300(1):E19-27. PubMed ID: 20823449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRH haplotype as a factor influencing cerebrospinal fluid levels of corticotropin-releasing hormone, hypothalamic-pituitary-adrenal axis activity, temperament, and alcohol consumption in rhesus macaques.
    Barr CS; Dvoskin RL; Yuan Q; Lipsky RH; Gupte M; Hu X; Zhou Z; Schwandt ML; Lindell SG; McKee M; Becker ML; Kling MA; Gold PW; Higley D; Heilig M; Suomi SJ; Goldman D
    Arch Gen Psychiatry; 2008 Aug; 65(8):934-44. PubMed ID: 18678798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corticotrophin releasing factor receptor 1 antagonists prevent chronic stress-induced behavioral changes and synapse loss in aged rats.
    Dong H; Keegan JM; Hong E; Gallardo C; Montalvo-Ortiz J; Wang B; Rice KC; Csernansky J
    Psychoneuroendocrinology; 2018 Apr; 90():92-101. PubMed ID: 29477954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corticotropin-releasing hormone receptors in the medial prefrontal cortex regulate hypothalamic-pituitary-adrenal activity and anxiety-related behavior regardless of prior stress experience.
    Jaferi A; Bhatnagar S
    Brain Res; 2007 Dec; 1186():212-23. PubMed ID: 18001698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracerebroventricular administration of corticotrophin-releasing hormone receptor antagonists produces different effects on hypothalamic pituitary adrenal responses to novel restraint depending on the stress history of the animal.
    Vining C; Iyer V; Bhatnagar S
    J Neuroendocrinol; 2007 Mar; 19(3):198-207. PubMed ID: 17280593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stress-induced behaviors require the corticotropin-releasing hormone (CRH) receptor, but not CRH.
    Weninger SC; Dunn AJ; Muglia LJ; Dikkes P; Miczek KA; Swiergiel AH; Berridge CW; Majzoub JA
    Proc Natl Acad Sci U S A; 1999 Jul; 96(14):8283-8. PubMed ID: 10393986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.